Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794087 | 0.81 | L3MBTL1 (0.64) | L3MBTL1TDP1CA2L3MBTL3ALDH1A1 | |
| SCHEMBL6794093 | 0.81 | L3MBTL1 (0.64) | L3MBTL1TDP1CA2L3MBTL3ALDH1A1 | |
| SCHEMBL15904138 | 0.76 | TDP1 (0.61) | L3MBTL1TDP1CA2ALDH1A1HPGD | |
| SCHEMBL6290809 | 0.75 | L3MBTL1 (0.57) | L3MBTL1TDP1CA2ALDH1A1SMN1; SMN2 | |
| SCHEMBL6290811 | 0.75 | L3MBTL1 (0.57) | L3MBTL1TDP1CA2ALDH1A1SMN1; SMN2 | |
| SCHEMBL15904148 | 0.74 | MAPK1 (0.47) | L3MBTL1L3MBTL3ALDH1A1HPGDPOLB | |
| SCHEMBL15904172 | 0.74 | GYS1 (0.48) | L3MBTL1TDP1CA2L3MBTL3ALDH1A1 | |
| SCHEMBL15904111 | 0.71 | ALDH1A1 (0.62) | L3MBTL1TDP1CA2ALDH1A1SMN1; SMN2 | |
| SCHEMBL3575901 | 0.71 | TDP1 (0.66) | L3MBTL1TDP1CA2ALDH1A1SMN1; SMN2 | |
| SCHEMBL3575904 | 0.71 | TDP1 (0.66) | L3MBTL1TDP1CA2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| EP-2948450-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014117090-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | L3MBTL1 1568/4885TDP1 1723/4885CA2 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.